Osiris Prochymal Gets Green Light In Canada; FDA Filing Is Next
This article was originally published in The Pink Sheet Daily
Executive Summary
World’s first approval for a stem cell treatment is milestone for Maryland-based Osiris Therapeutics, but the product’s patient population is small and further studies are required.
You may also be interested in...
Geron Restructuring Sours Investors As Company Bets On Cancer
The pioneering U.S. biotech will look to partner its five human embryonic stem cell research programs while focusing entirely on two mid-stage cancer assets.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.